Halozyme Therapeutics, Inc.
HALO
$64.66
-$1.88-2.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.19% | 34.97% | 25.65% | 22.44% | 21.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.19% | 34.97% | 25.65% | 22.44% | 21.35% |
| Cost of Revenue | 9.48% | 5.21% | -10.37% | -24.96% | -18.08% |
| Gross Profit | 37.48% | 44.81% | 40.11% | 45.16% | 41.01% |
| SG&A Expenses | 15.11% | 16.52% | 9.94% | 3.45% | 17.48% |
| Depreciation & Amortization | 0.00% | -0.11% | -0.21% | -0.31% | 22.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.46% | 5.82% | 1.18% | -5.18% | 5.63% |
| Operating Income | 54.59% | 68.73% | 56.48% | 62.16% | 42.20% |
| Income Before Tax | 55.37% | 66.09% | 54.27% | 59.94% | 51.00% |
| Income Tax Expenses | 71.69% | 69.81% | 63.08% | 69.39% | 36.84% |
| Earnings from Continuing Operations | 51.73% | 65.22% | 52.25% | 57.71% | 54.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.73% | 65.22% | 52.25% | 57.71% | 54.57% |
| EBIT | 54.59% | 68.73% | 56.48% | 62.16% | 42.20% |
| EBITDA | 47.07% | 57.78% | 46.86% | 50.41% | 38.69% |
| EPS Basic | 59.02% | 71.10% | 57.10% | 63.48% | 61.49% |
| Normalized Basic EPS | 63.55% | 77.48% | 64.59% | 71.40% | 52.23% |
| EPS Diluted | 57.13% | 69.17% | 55.18% | 62.32% | 60.60% |
| Normalized Diluted EPS | 61.90% | 76.05% | 63.33% | 70.67% | 52.12% |
| Average Basic Shares Outstanding | -4.27% | -3.35% | -3.10% | -3.88% | -4.50% |
| Average Diluted Shares Outstanding | -3.31% | -2.54% | -2.38% | -3.60% | -4.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |